Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nyxoah SA (NYXH : NSDQ)

• Company Description    Nyxoah SA is a medical technology company. It focused on the development and commercialization of solutions to treat Obstructive Sleep Apnea. Nyxoah SA is based in Belgium. Number of Employees: 184

• Price / Volume Information    Yesterday's Closing Price: $4.60 Daily Weekly Monthly 20 Day Moving Average: 24,362 shares Shares Outstanding: 34.06 (millions) Market Capitalization: $156.68 (millions) Beta: 1.55 52 Week High: $11.87 52 Week Low: $4.35 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.37% -4.20% 12 Week -28.01% -29.17% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL RUE EDOUARD BELIN 12 - MONT-SAINT-GUIBERT,C9 1435 BEL ph: 321-022-2355 fax: 321-045-9075 ir@nyxoah.com http://www.nyxoah.com

• General Corporate Information    Officers Olivier Taelman - Chief Executive Officer Robelga SRL - Chairman John Landry - Chief Financial Officer Kevin Rakin - Director Pierre Gianello - Director Peer Information Nyxoah SA (HLIS) Nyxoah SA (AZTA) Nyxoah SA (APYI) Nyxoah SA (RNVA) Nyxoah SA (HMSY) Nyxoah SA (LRSI) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MEDICAL INFO SYS Sector: Medical CUSIP: B6S7WD106 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/12/26 Share - Related Items Shares Outstanding: 34.06 Most Recent Split Date: (:1) Beta: 1.55 Market Capitalization: $156.68 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.54 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.47 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.80 Price/Cash Flow: - Price / Sales: 24.90 EPS Growth vs. Year Ago Period: -34.55% vs. Previous Quarter: -17.46% Sales Growth vs. Year Ago Period: 65.71% vs. Previous Quarter: 51.64% ROE 12/31/25 - - 09/30/25 - -101.99 06/30/25 - -79.18 ROA 12/31/25 - - 09/30/25 - -66.74 06/30/25 - -54.92 Current Ratio 12/31/25 - - 09/30/25 - 1.70 06/30/25 - 2.63 Quick Ratio 12/31/25 - - 09/30/25 - 1.41 06/30/25 - 2.38 Operating Margin 12/31/25 - - 09/30/25 - -1,457.97 06/30/25 - -1,541.84 Net Margin 12/31/25 - - 09/30/25 - -1,457.97 06/30/25 - -1,541.84 Pre-Tax Margin 12/31/25 - - 09/30/25 - -1,411.65 06/30/25 - -1,508.78 Book Value 12/31/25 - - 09/30/25 - 1.64 06/30/25 - 2.45 Inventory Turnover 12/31/25 - - 09/30/25 - 0.38 06/30/25 - 0.34 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.40 06/30/25 - 0.29 Debt-to-Capital 12/31/25 - - 09/30/25 - 28.36 06/30/25 - 22.32

Powered by Zacks Investment Research ©